showed that the integrated analysis of circulating tumor DNAs and DNAs in tumor tissue could improve the detection rate of CTNNB1 mutation in HCC patients (110), indicating that the combined analysis of tumor tissue and blood might better select HCC patients suitable for immunotherapy. This evidence concerns the gene CTNNB1 and neoplasm.